Abstract
A clinical trial using human embryonic stem cell (hESC) therapy for an inherited retinal degenerative disease is about to commence. The Advanced Cell Technology (ACT) trial will treat patients with Stargardt's macular dystrophy using transplanted retinal pigment epithelium derived from hESCs. Currently, no effective treatment is available for Stargardt's disease so a stem cell-based therapy that can slow progression of this blinding condition could represent a significant breakthrough. While there are some hurdles to clear, the ACT trial is a fine example of translational research that could eventually pave the way for a range of stem cell therapies for the retina and other tissues.
| Original language | English |
|---|---|
| Article number | 47 |
| Pages (from-to) | 47-50 |
| Number of pages | 4 |
| Journal | Stem Cell Research & Therapy |
| Volume | 2 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2011 |
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology (miscellaneous)
- Cell Biology
- Molecular Medicine
- General Medicine
- Medicine (miscellaneous)
